PMID- 32394047
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20221207
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 25
IP  - 8
DP  - 2020 Aug
TI  - Efficacy and safety of nivolumab for renal cell carcinoma in patients over 
      75 years old from multiple Japanese institutes.
PG  - 1543-1550
LID - 10.1007/s10147-020-01693-y [doi]
AB  - PURPOSE: Despite nivolumab being increasingly used for treating metastatic renal 
      cell carcinoma (mRCC), differing findings have been reported about its efficacy 
      and safety in elderly patients. Thus, this study was aimed at evaluating 
      nivolumab's efficacy and safety for treating mRCC in Japanese patients 
      aged >/= 75 years. METHODS: From March 2013 to August 2019, 118 mRCC patients (89 
      men and 29 women) were treated with nivolumab. The objective response rates 
      (ORRs) were compared between patients aged >/= 75 and < 75 years. Progression-free 
      survival (PFS), overall survival (OS), and adverse events (AEs) were also 
      compared between the two age-groups. RESULTS: The median follow-up duration after 
      nivolumab initiation was 10 months. At the time of nivolumab initiation, 22 and 
      96 patients were aged >/= 75 and < 75 years, respectively. Intergroup differences 
      in patient characteristics except for age were not significant. Furthermore, 
      intergroup differences in ORR (14 vs 23%; P = 0.367), PFS (HR 0.74, 95% CI 
      0.37-1.51; P = 0.414), and median OS (HR 1.29, 95% CI 0.68-2.46; P = 0.433) were 
      not significant. The incidence of nivolumab discontinuation due to AEs was 
      significantly higher in the >/= 75 years group (27% vs 7%; P = 0.028), although the 
      intergroup difference in the AE incidence rate was not significant (55% vs 43.8%; 
      P = 0.535). CONCLUSIONS: Nivolumab's effectiveness was comparable between the two 
      patient groups, except for early AE-related discontinuation in the >/= 75 year 
      group.
FAU - Numakura, Kazuyuki
AU  - Numakura K
AUID- ORCID: 0000-0002-5899-1738
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan. numakura@doc.med.akita-u.ac.jp.
FAU - Kobayashi, Mizuki
AU  - Kobayashi M
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Hatakeyama, Shingo
AU  - Hatakeyama S
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Naito, Sei
AU  - Naito S
AD  - Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
FAU - Horikawa, Yohei
AU  - Horikawa Y
AD  - Department of Urology, Japanese Red Cross Akita Hospital, Akita, Japan.
FAU - Tanaka, Toshikazu
AU  - Tanaka T
AD  - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan.
FAU - Kamada, Sachiko
AU  - Kamada S
AD  - Department of Neurology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Muto, Yumina
AU  - Muto Y
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Yamamoto, Ryohei
AU  - Yamamoto R
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Koizumi, Atsushi
AU  - Koizumi A
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Nara, Taketoshi
AU  - Nara T
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Kanda, Sohei
AU  - Kanda S
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Saito, Mitsuru
AU  - Saito M
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Narita, Shintaro
AU  - Narita S
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Inoue, Takamitsu
AU  - Inoue T
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
FAU - Shimoda, Naotake
AU  - Shimoda N
AD  - Department of Urology, Japanese Red Cross Akita Hospital, Akita, Japan.
FAU - Tsuchiya, Norihiko
AU  - Tsuchiya N
AD  - Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
FAU - Ohyama, Chikara
AU  - Ohyama C
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Habuchi, Tomonori
AU  - Habuchi T
AD  - Department of Urology, Akita University Graduate School of Medicine, Akita, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200511
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - Asian People
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/adverse effects/*therapeutic use
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 75 years or older
OT  - Efficacy
OT  - Nivolumab
OT  - Renal cell carcinoma
OT  - Tolerability
EDAT- 2020/05/13 06:00
MHDA- 2020/10/02 06:00
CRDT- 2020/05/13 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/05/13 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2020/05/13 06:00 [entrez]
AID - 10.1007/s10147-020-01693-y [pii]
AID - 10.1007/s10147-020-01693-y [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2020 Aug;25(8):1543-1550. doi: 10.1007/s10147-020-01693-y. Epub 
      2020 May 11.